Profile data is unavailable for this security.
About the company
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Its lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
- Revenue in USD (TTM)0.00
- Net income in USD-121.24m
- Incorporated1994
- Employees202.00
- LocationOmeros Corp201 Elliott Avenue WestSEATTLE 98119United StatesUSA
- Phone+1 (206) 676-5000
- Fax+1 (206) 676-5005
- Websitehttps://www.omeros.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maravai Lifesciences Holdings Inc | 192.28m | -121.24m | 756.89m | 550.00 | -- | 3.08 | -- | 3.94 | -0.8442 | -0.8442 | 1.34 | 0.961 | 0.1808 | 3.18 | 7.48 | 337,338.60 | -20.14 | 8.27 | -27.68 | 10.45 | 20.86 | 72.61 | -111.42 | 25.48 | 4.56 | -7.37 | 0.4288 | 0.00 | -10.30 | 12.61 | -21.69 | -- | 12.69 | -- |
| MiMedx Group Inc | 393.44m | 40.83m | 758.28m | 837.00 | 18.75 | 3.17 | 13.67 | 1.93 | 0.273 | 0.273 | 2.63 | 1.61 | 1.40 | 2.79 | 5.95 | 470,062.10 | 14.51 | 2.94 | 17.63 | 3.89 | 81.99 | 83.00 | 10.38 | 2.07 | 3.95 | -- | 0.0708 | -- | 8.52 | 3.12 | -24.73 | -- | -5.37 | -- |
| Arbutus Biopharma Corp | 14.61m | -42.28m | 765.45m | 44.00 | -- | 9.87 | -- | 52.41 | -0.2219 | -0.2219 | 0.0764 | 0.4032 | 0.1227 | -- | 11.62 | 331,954.50 | -35.50 | -44.03 | -39.50 | -49.46 | -- | -- | -289.45 | -433.59 | -- | -- | 0.0454 | -- | -65.98 | 0.5268 | 4.02 | -- | -20.93 | -- |
| Bicara Therapeutics Inc | 0.00 | -121.52m | 778.45m | 55.00 | -- | 1.93 | -- | -- | -5.03 | -5.03 | 0.00 | 7.38 | 0.00 | -- | -- | 0.00 | -25.61 | -- | -26.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.80 | -- | -- | -- |
| MapLight Therapeutics Inc | 0.00 | -92.43m | 781.32m | 109.00 | -- | -- | -- | -- | -2.23 | -2.23 | 0.00 | 1.54 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -39.26 | -- | -- | -- |
| Janux Therapeutics Inc | 10.00m | -101.90m | 790.34m | 74.00 | -- | 0.809 | -- | 79.03 | -1.67 | -1.67 | 0.1649 | 16.24 | 0.0116 | -- | -- | 135,135.10 | -11.85 | -13.75 | -12.17 | -14.23 | -- | -- | -1,018.95 | -743.21 | -- | -- | 0.00 | -- | 30.99 | -- | -18.36 | -- | -- | -- |
| Eikon Therapeutics Inc | -100.00bn | -100.00bn | 812.46m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.7508 | -- | -- | -- |
| BIOAGE Labs Inc | 5.92m | -75.79m | 817.00m | 62.00 | -- | 2.53 | -- | 138.08 | -2.04 | -2.04 | 0.1594 | 7.74 | 0.0184 | -- | -- | 95,435.48 | -23.59 | -- | -25.31 | -- | -- | -- | -1,280.90 | -- | -- | -- | 0.0147 | -- | -- | -- | -11.36 | -- | -- | -- |
| Xencor Inc | 167.36m | -138.75m | 827.65m | 250.00 | -- | 1.32 | -- | 4.95 | -1.88 | -1.88 | 2.26 | 8.76 | 0.1807 | -- | 10.46 | 669,428.00 | -15.07 | -9.89 | -16.65 | -10.95 | -- | -- | -83.42 | -48.58 | -- | -12.12 | 0.1755 | -- | -36.72 | -6.75 | -74.73 | -- | -2.93 | -- |
| Omeros Corp | 0.00 | -121.24m | 828.83m | 202.00 | -- | -- | -- | -- | -2.04 | -2.02 | 0.00 | -3.15 | 0.00 | -- | -- | 0.00 | -48.59 | -50.90 | -66.86 | -63.20 | -- | -- | -- | -- | -- | -- | 2.72 | -- | -- | -- | -4.41 | -- | -13.15 | -- |
| SS Innovations International Inc | 33.57m | -17.11m | 834.51m | 378.00 | -- | 21.04 | -- | 24.86 | -0.0959 | -0.0959 | 0.1822 | 0.2048 | 0.6253 | 1.19 | 5.09 | 88,820.32 | -31.86 | -77.47 | -50.87 | -137.45 | 48.25 | 23.69 | -50.96 | -169.09 | 1.34 | -- | 0.2025 | -- | 251.46 | -- | 8.27 | -- | 67.53 | -- |
| ARS Pharmaceuticals Inc | 142.77m | -80.04m | 874.81m | 162.00 | -- | 5.92 | -- | 6.13 | -0.9012 | -0.9012 | 1.38 | 1.49 | 0.4836 | 3.56 | 7.67 | 921,109.70 | -27.11 | -14.27 | -30.61 | -14.82 | 89.40 | -- | -56.06 | -224.85 | 6.51 | -- | 0.3946 | -- | 297,063.30 | -- | 114.71 | -- | 42.45 | -- |
| Aktis Oncology Inc | 5.56m | -60.65m | 899.53m | -- | -- | -- | -- | 161.79 | -1.20 | -1.20 | 0.1098 | 3.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,090.81 | -- | -- | -- | 0.00 | -- | -- | -- | -53.56 | -- | -- | -- |
| BridgeBio Oncology Therapeutics Inc | 0.00 | 4.72m | 899.87m | -- | 56.36 | 1.40 | -- | -- | 0.1996 | 0.1996 | 0.00 | 8.05 | 0.00 | -- | -- | -- | 2.44 | -- | 2.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18,328.62 | -- | -- | -- |
| CytomX Therapeutics Inc | 113.63m | 28.02m | 901.40m | 119.00 | 13.21 | 8.18 | 30.77 | 7.93 | 0.4027 | 0.4027 | 0.9733 | 0.6506 | 0.7646 | -- | 45.63 | 954,882.40 | 18.85 | -15.58 | 40.91 | -26.48 | -- | -- | 24.66 | -50.39 | -- | -- | 0.00 | -- | 36.45 | 19.16 | 5,700.88 | -- | -38.41 | -- |
Data as of Feb 13 2026. Currency figures normalised to Omeros Corp's reporting currency: US Dollar USD
30.82%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 4.58m | 6.47% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.50m | 4.94% |
| Ingalls & Snyder LLCas of 31 Dec 2025 | 3.45m | 4.86% |
| UBS Securities LLCas of 31 Dec 2025 | 1.86m | 2.63% |
| Stifel Nicolaus & Co., Inc. (Investment Management)as of 31 Dec 2025 | 1.81m | 2.55% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.63m | 2.30% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 1.57m | 2.22% |
| Polar Asset Management Partners, Inc.as of 30 Sep 2025 | 1.50m | 2.11% |
| D. E. Shaw & Co. LPas of 30 Sep 2025 | 1.01m | 1.42% |
| Two Sigma Investments LPas of 30 Sep 2025 | 933.31k | 1.32% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
